Platform Technology Lifecycle

Once a core technology demonstrates reusability, early-stage investors support its application across multiple disease indications rather than optimization for a single disease. In later funding rounds, capital expects to see evidence of the platform's multi-pipeline validation, manufacturing scale-up, and global expansion—not merely clinical breakthroughs in a single product.

Read the daily articles behind this idea on the Chinese edition.